inactivation apoptosis effector apaf- malignant melanoma 
metastatic melanoma deadly cancer fails respond conventional chemotherapy poorly understood molecular level1 p53 mutations often occur aggressive chemoresistant cancers rarely observed melanoma12 show metastatic melanomas often lose apaf- cell-death effector acts cytochrome c caspase- mediate p53-dependent apoptosis3 loss apaf- expression accompanied allelic loss metastatic melanomas can recovered melanoma cell lines treatment methylation inhibitor -aza--deoxycytidine 5aza2dc apaf--negative melanomas invariably chemoresistant unable execute typical apoptotic programme response p53 activation restoring physiological levels apaf- gene transfer 5aza2dc treatment markedly enhances chemosensitivity rescues apoptotic defects associated apaf- loss conclude apaf- inactivated metastatic melanomas leads defects execution apoptotic cell death apaf- loss may contribute low frequency p53 mutations observed highly chemoresistant tumour type 
